Catriona Yale Akero Therapeutics, Inc. (AKRO) insider trading activity

Catriona Yale is Chief Development Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 74,158 shares of AKRO, which is worth approximately $2.36 Million. The most recent transaction as insider was on Aug 23, 2024, when has been sold 8,851 shares (Common Stock) at a price of $27.53 per share, resulting in proceeds of $243,668. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 74.2K

2.34% 3M change

61.18% 12M change

Total Value Held $2.36 Million

Catriona Yale Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 23 2024	SELL Open market or private sale	$243,668 $27.53 p/Share	8,851 Reduced 10.44%	75,931 Common Stock
Aug 23 2024	BUY Exercise of conversion of derivative security	$5,487 $0.62 p/Share	8,851 Added 9.45%	84,782 Common Stock
Jun 28 2024	BUY Grant, award, or other acquisition	$21,216 $19.94 p/Share	1,064 Added 1.38%	75,931 Common Stock
Jun 11 2024	SELL Open market or private sale	$63,958 $22.64 p/Share	2,825 Reduced 3.64%	74,867 Common Stock
Mar 13 2024	SELL Open market or private sale	$20,482 $28.33 p/Share	723 Reduced 0.92%	77,692 Common Stock
Mar 04 2024	SELL Open market or private sale	$732,726 $35.49 p/Share	20,646 Reduced 20.84%	78,415 Common Stock
Mar 04 2024	BUY Exercise of conversion of derivative security	$283,469 $13.73 p/Share	20,646 Added 17.25%	99,061 Common Stock
Dec 14 2023	SELL Open market or private sale	$12,393 $20.76 p/Share	597 Reduced 0.76%	77,910 Common Stock
Dec 08 2023	BUY Grant, award, or other acquisition	-	32,497 Added 29.28%	78,507 Common Stock
Sep 21 2023	SELL Open market or private sale	$240,550 $48.11 p/Share	5,000 Reduced 9.8%	46,010 Common Stock
Sep 21 2023	BUY Exercise of conversion of derivative security	$31,800 $6.36 p/Share	5,000 Added 8.93%	51,010 Common Stock
Sep 13 2023	SELL Open market or private sale	$31,059 $50.34 p/Share	617 Reduced 1.32%	46,010 Common Stock
Aug 28 2023	SELL Open market or private sale	$288,916 $50.29 p/Share	5,745 Reduced 10.97%	46,627 Common Stock
Aug 28 2023	BUY Exercise of conversion of derivative security	$36,538 $6.36 p/Share	5,745 Added 9.89%	52,372 Common Stock
Jun 23 2023	SELL Open market or private sale	$561,770 $51.07 p/Share	11,000 Reduced 19.09%	46,627 Common Stock
Jun 22 2023	SELL Open market or private sale	$573,980 $52.18 p/Share	11,000 Reduced 16.03%	57,627 Common Stock
Jun 21 2023	SELL Open market or private sale	$593,098 $52.26 p/Share	11,349 Reduced 14.19%	68,627 Common Stock
Jun 13 2023	SELL Open market or private sale	$32,599 $55.16 p/Share	591 Reduced 0.73%	79,976 Common Stock
Mar 10 2023	SELL Payment of exercise price or tax liability	$30,465 $43.46 p/Share	701 Reduced 0.86%	80,567 Common Stock
Jan 13 2023	SELL Open market or private sale	$252,750 $50.55 p/Share	5,000 Reduced 5.8%	81,268 Common Stock
Dec 12 2022	SELL Open market or private sale	$217,399 $43.48 p/Share	5,000 Reduced 5.48%	86,268 Common Stock
Dec 09 2022	BUY Grant, award, or other acquisition	-	19,195 Added 17.38%	91,268 Common Stock
Nov 10 2022	SELL Open market or private sale	$198,400 $39.68 p/Share	5,000 Reduced 6.49%	72,073 Common Stock
Oct 10 2022	SELL Open market or private sale	$189,950 $37.99 p/Share	5,000 Reduced 6.09%	77,073 Common Stock
Sep 13 2022	SELL Open market or private sale	$1,104,400 $27.61 p/Share	40,000 Reduced 32.77%	82,073 Common Stock

Catriona Yale

Chief Development Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account